Introduction: The adenoviral keratoconjunctivitis infiltrates may be a source of significant visual impairment justifying the use of various therapeutic means.

Aim: Evaluate the efficiency and safety of use of cyclosporine A 0,5% eye drop in the treatment of subepithelial infiltrates.

Methods: It was a prospective study of 37 eyes of 22 patients with adenoviral keratoconjunctivitis with subepithelial infiltrates treated with cyclosporine A 0,5% eye drop. Cyclosporine A 0,5% was prepared from the injectable form of cyclosporine (Sandimmun®) and artificial tears. The cyclosporine A 0,5% was first administered at 4 drops per day for 15 days, then at a rate of 2 drops per day for a variable period ranging from 15 days to 6 months. The use of this molecule has been motivated by the presence of a persistent dazzlement, by visual acuity under 6/10 or an astigmatism superior to 1 diopter.

Results: At the end of follow, dazzlement disappeared in all patients; the final average visual acuity was 8/10 and corneal astigmatism average was of 0.75 diopter. The slit lamp examination showed a marked decrease in the number and density of subepithelial infiltrates from the 15th day. A 29-year-old patient, however, presented some intercostal vesicles due to zonal recrudescence but with spontaneous and quick resolve in the same time of taking topical cyclosporine. No local complications were observed in our patients. The average follow-up was 13 months.

Conclusion: Topical cyclosporine A is an effective and well-tolerated alternative to corticosteroids in the subepithelial infiltrates occurring as sequelae of adenoviral keratoconjunctivitis.

Download full-text PDF

Source

Publication Analysis

Top Keywords

adenoviral keratoconjunctivitis
16
cyclosporine 05%
16
eye drop
12
subepithelial infiltrates
12
keratoconjunctivitis infiltrates
8
05% eye
8
drops day
8
visual acuity
8
topical cyclosporine
8
cyclosporine
7

Similar Publications

Certain species D human adenoviruses (HAdV-D19, -D37, and -D64) are causative agents of epidemic keratoconjunctivitis. HAdV-D37 has previously been shown to bind CD46 (membrane cofactor protein) and sialic acid as adhesion receptors. HAdV-D64 is genetically highly similar to HAdV-D37, with an identical fiber protein sequence, but differs substantially in its penton base and hexon proteins, two other major capsid components, due to genetic recombination.

View Article and Find Full Text PDF

Background: Blepharoconjunctivitis poses a diagnostic challenge due to its diverse etiology, including viral infections. Blepharoconjunctivits can be acute or chronic, self-limiting, or needing medical therapy.

Aim: To review possible viral agents crucial for accurate differential diagnosis in cases of blepharoconjunctivitis.

View Article and Find Full Text PDF
Article Synopsis
  • North India experiences an annual outbreak of viral conjunctivitis during the monsoon season, impacting a large number of people, most of whom recover without treatment.
  • Patients with a history of trabeculectomy (eye surgery for glaucoma) are at increased risk as conjunctivitis can lead to serious complications like blebitis and bacterial/fungal infections.
  • It's crucial to educate these patients about the conjunctivitis outbreak and the warning signs that require immediate medical attention to prevent complications.
View Article and Find Full Text PDF
Article Synopsis
  • Corneal subepithelial infiltrates (SEIs) can lead to vision problems in patients with adenoviral keratoconjunctivitis (AKC), often causing irregular astigmatism that is overlooked.
  • An 8-year-old girl with AKC experienced recurring vision issues despite treatment, revealing that her vision loss was due to an irregular corneal surface rather than corneal opacity.
  • Treatment with 0.1% tacrolimus eye drops proved effective in addressing both the corneal opacity and the irregular surfaces, emphasizing the importance of using Placido ring topography for diagnosis and monitoring.
View Article and Find Full Text PDF

Purpose: To investigate the effect of topical Polyvinylpyrrolidone-iodine (PVP-I) 0.6% on the clinical course of adenoviral keratoconjunctivitis compared with PVP-I 1% and artificial tears.

Methods: We prospectively enrolled all patients over 18 years of age with a polymerase chain reaction (PCR)-confirmed diagnosis of adenoviral keratoconjunctivitis who presented to the hospital between November 2022 and June 2023.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!